Skip to content
Screener

LivaNova LIVN Stock-Based Comp

Stock-Based Comp at other companies

Abbott logo
AbbottABT
$168M+18.3%
Haemonetics logo
HaemoneticsHAE
$9.31M0.0%
Neuropace, Inc. logo
Neuropace, Inc.NPCE
$2.28M-13.3%
Inspire Medical Systems logo
Inspire Medical SystemsINSP
$30.69M-1.2%
Medtronic logo
MedtronicMDT
$95M+6.7%
ITG
Integer HoldingsITGR
$6.66M-3.2%

Other financials

Income statement

See full
Revenue$390.6M+10.8%
Gross profit$273.7M+14.5%
Operating income$49.5M-8.7%
Net income$108.6M+300%
EPS (diluted)$1.93+286%

Balance sheet

See full
Cash & equivalents$516.6M-13.0%
Total debt$348.5M-27.8%
Total equity$1.3B+18.0%
Total assets$2.6B+5.4%

Cash flow

See full
Operating cash flow$66.6M+5.8%
CapEx$31.6M+108%
Free cash flow$35.0M-26.7%

Valuation

See full
Market cap$4.17B+61.5%
Enterprise value$4.01B+61.9%
P/E22.6×-67.9×
P/S2.8×+0.9×

Profitability

See full
Gross margin68.1%+0.1pp
Operating margin12.7%-0.7pp
Net margin-16.1%-18.0pp
FCF margin10.1%-2.3pp

Returns & leverage

See full
Return on equity-17.6%-19.5pp
Debt / equity0.3×-0.2×
Current ratio1.4×+0.2×

Where this comes from

Reported directly by LivaNova in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The source filing: LivaNova’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 2:23 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001639691-26-000090
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Deferred income tax (benefit) expense(89,945)2,763
Remeasurement of derivative instruments52,213(27,260)
Share-based compensation25,15216,957
Depreciation17,05213,293
Gain on sale of investment(13,648)
Amortization of intangible assets11,2268,656
Remeasurement of contingent consideration to fair value10,5043,709

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is LivaNova's stock-based comp?
LivaNova (LIVN) reported stock-based comp of $16.88M in Q2 2026.
How has LivaNova's stock-based comp changed year-over-year?
LivaNova's stock-based comp increased by 84.0% year-over-year, from $9.17M to $16.88M.
What is the long-term trend for LivaNova's stock-based comp?
Over 4 years (2021 to 2025), LivaNova's stock-based comp has grown at a -2.7% compound annual growth rate (CAGR), from $40.56M to $36.29M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Ask your AI about LivaNova's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude